Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa.
D000583:Amikacin / Q000494:pharmacology; D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001390:Azlocillin; D002228:Carbenicillin / Q000494:pharmacology*; D002439:Cefotaxime; D002441:Cefsulodin; D002511:Cephalosporins / Q000494:pharmacology*; D003982:Dibekacin / Q000494:pharmacology; D004357:Drug Synergism; D005839:Gentamicins / Q000494:pharmacology; D008802:Mezlocillin; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012853:Sisomicin / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005839:Gentamicins; D010406:Penicillins; D003982:Dibekacin; D000583:Amikacin; D002228:Carbenicillin; D001390:Azlocillin; D002439:Cefotaxime; D008802:Mezlocillin; D002441:Cefsulodin; D014031:Tobramycin; D012853:Sisomicin